Filtered By:
Condition: Atrial Fibrillation
Management: Funding
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 31 results found since Jan 2013.
Decision on funding of dabigatran in Australia delayed
Source: National Prescribing Service (Australia)
Area: News
In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended dabigatran for stroke prevention in atrial fibrillation (AF) for public funding in March 2011. Such a positive committee verdict usually ensures smooth passage into the national Pharmaceutical Benefits Scheme (PBS), but the Australian Minister for Health announced in December 2012 that the PBAC decision is being delayed. This follows the release of a report reviewing anticoagulation therapies in AF which identified uncertainties regarding the magnitude of any incremental clinical and ...
Source: NeLM - Cardiovascular Medicine - January 17, 2013 Category: Cardiology Source Type: news
